Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

This study is testing a cutting-edge immune cell therapy for advanced pancreatic cancer. The treatment takes a patient's own T cells (immune cells), engineers them in the lab to recognize a specific cancer mutation called KRAS G12V, then infuses them back to attack the cancer. This approach is highly personalized because it targets a mutation found in many pancreatic cancers. **You may be eligible if...** - You have advanced or metastatic pancreatic cancer confirmed by biopsy - Your tumor has the KRAS G12V mutation (or a similar mutation in HRAS or NRAS) - You carry a specific immune marker called HLA-A*11:01 - You are between 18 and 75 years old - You are in good physical condition (ECOG 0 or 1) - You have received standard chemotherapy previously **You may NOT be eligible if...** - Your tumor does not have the required mutation - You do not carry the HLA-A*11:01 marker - You are not willing to use birth control during the study Talk to your doctor to see if this trial is right for you.